<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77403">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117245</url>
  </required_header>
  <id_info>
    <org_study_id>265-105</org_study_id>
    <nct_id>NCT02117245</nct_id>
  </id_info>
  <brief_title>Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers</brief_title>
  <official_title>Phase I Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MethylGene Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MethylGene Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the bioavailability of the MGCD265 formulation
      following oral administration under fed conditions (Treatment-1) as compared to fasting
      conditions (Treatment-2) in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to assess the bioavailability of the MGCD265 formulation following
      oral administration under fed conditions (Treatment-1) as compared to fasting conditions
      (Treatment-2) in healthy male and female volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Peak Plasma concentration (Cmax) of MGCD265.</measure>
    <time_frame>26 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bioavailability of study drug under fed conditions compared to fasting conditions in healthy male and female volunteers.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pharmacodynamic analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy male and female volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female volunteer

          2. Volunteer age of 40 to 65 years

          3. Females of childbearing potential using a stable contraceptive method at least 14
             days prior to screening and willing to use acceptable birth control methods from 7
             days prior to first dose until 30 days after last dose of study drug:

          4. Female volunteers will be considered of non childbearing potential and eligible if:

               -  Amenorrhea for at least 1 year;

               -  Hysterectomy;

               -  Bilateral oophorectomy at least 6 weeks prior to first dose;

               -  Bilateral tubal ligation at least 6 months prior to first dose;

               -  Hysteroscopic sterilization.

          5. Male volunteers who agree to be abstinent or use acceptable contraception methods in
             collaboration with their female partner from the time of taking the first dose until
             90 days after the last dose of study drug:

             â€¢     Male volunteers who also agree to not donate sperm from the time of taking the
             first dose until 90 days after the last dose.

          6. Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00
             kg/m2

          7. Non- or ex smokers for at least 6 months.

          8. Availability for the entire study period

          9. Motivated volunteer and absence of intellectual problems likely to limit the validity
             of consent to participate in the study or the compliance with protocol requirements

         10. Clinical laboratory values within the laboratory's stated normal range; or they must
             be without any clinical significance

         11. Have no clinically significant diseases captured in medical history or evidence of
             clinically significant findings on physical examination and/or clinical laboratory
             evaluations

         12. Willingness to adhere to protocol requirements

        The informed consent form must be signed by all volunteers, prior to participation in the
        study.

        Exclusion Criteria:

          1. Females who are pregnant or are lactating

          2. History of significant hypersensitivity reactions to any substance or drug

          3. History or presence of significant gastrointestinal, liver or kidney disease, or any
             other conditions known to interfere with absorption, distribution, metabolism or
             excretion of drugs

          4. Seated blood pressure higher than and equal to 140/90 mmHg at screening

          5. Seated blood pressure higher than and equal to 140/90 mmHg before drug administration

          6. History or predisposition to cardiovascular illness

          7. History or predisposition to thrombotic or hemorrhagic events, bleeding diathesis or
             coagulopathy, gastrointestinal or other conditions with risk of perforation, presence
             of a non-healing wound, ulcer or fracture

          8. Presence of significant pulmonary, hematologic, neurological, psychiatric, endocrine,
             immunologic or dermatologic disease

          9. No major surgery within 28 days prior to first dose

         10. Suicidal tendency, disposition to seizures, state of confusion, clinically relevant
             psychiatric diseases

         11. Presence of out-of-range cardiac interval or ECG abnormalities

         12. Maintenance therapy with any drug, or history of drug dependency or alcohol abuse

         13. Any clinically significant illness in the previous 28 days before day 1 of study

         14. Use of any enzyme-modifying drugs in the previous 28 days before day 1 of study

         15. Use of any drugs known to induce or inhibit hepatic metabolism in the previous 28
             days before day 1 of study

         16. Any history of tuberculosis and/or prophylaxis for tuberculosis

         17. Positive urine screening of ethanol and/or drugs of abuse

         18. Positive results to HIV, HBsAg or anti-Hepatitis C Virus tests

         19. Females who are pregnant

         20. Volunteers who took an Investigational Product or donated 50 mL or more of blood in
             the previous 28 days before day 1 of this study

         21. Donation of 500 mL or more of blood in the previous 56 days before day 1 of this
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Juretic</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>May 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect on MGCD265 bioavailability in healthy volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
